Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of DWP14012 Tablet A vs Tablet B in Healthy Volunteers
NCT04185805Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area under the drug concentration-time curve from time 0 to tau at 48 hour and Peak concentration at 48 hour. Status: unknown.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04185805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185805.